期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
布地奈德吸入时机对轻度持续性哮喘儿童肺功能及生长发育的影响 被引量:2
1
作者 王兴宏 赵珊珊 尤登攀 《中国合理用药探索》 2022年第7期12-17,共6页
目的:探讨布地奈德吸入时机对轻度持续性哮喘儿童肺功能及生长发育的影响。方法:选取2019年1月~2020年6月收治的轻度持续性哮喘儿童86例作为研究对象,采用随机数字表法分为A组和B组,每组43例。A组行布地奈德持续吸入治疗,B组在患儿出现... 目的:探讨布地奈德吸入时机对轻度持续性哮喘儿童肺功能及生长发育的影响。方法:选取2019年1月~2020年6月收治的轻度持续性哮喘儿童86例作为研究对象,采用随机数字表法分为A组和B组,每组43例。A组行布地奈德持续吸入治疗,B组在患儿出现哮喘征兆时间断吸入布地奈德治疗,两组患儿均持续治疗6周,并持续随访观察至少1年。评价比较两组患儿治疗前,治疗后,随访3、6个月和12个月的哮喘日间症状评分和夜间症状评分,并检测比较两组同期第1秒用力呼气容积占预计值百分比(FEV_(1)%pred)和呼气峰流速占预计值百分比(PEF%pred)。比较两组随访12个月的身高增长值以及治疗前、随访6个月和12个月的体重指数(BMI)。比较两组患儿治疗1年期间哮喘发作次数、不良反应发生率。结果:两组治疗后、随访3、6个月和12个月的哮喘日间症状评分和夜间症状评分均低于治疗前,而FEV_(1)%pred和PEF%pred高于治疗前(P<0.05);且A组随访3、6个月和12个月的哮喘日间症状评分和夜间症状评分低于B组,而FEV_(1)%pred和PEF%pred高于B组(P<0.05)。两组随访12个月的身高增长值以及治疗前、随访6个月和随访12个月的BMI比较无统计学差异(P>0.05)。A组治疗1年期间哮喘发作次数低于B组(P<0.05)。两组声音嘶哑、口腔真菌感染、皮肤瘙痒等不良反应发生率比较无统计学差异(P>0.05)。结论:布地奈德持续吸入和间断吸入均有助于改善轻度持续性哮喘儿童的哮喘症状和肺功能,且2种给药方案对儿童生长发育的影响无统计学差异。布地奈德持续吸入更有利于改善轻度持续性哮喘儿童的哮喘症状和肺功能。 展开更多
关键词 布地奈德 吸入时机 轻度持续性哮喘 肺功能 生长发育
下载PDF
医疗吸氧的变革——智能吸氧计时系统
2
作者 喻波 彭健 +2 位作者 刘洪兵 陈叙 田贵全 《医用气体工程》 2017年第1期25-27,共3页
目前国内医院吸氧计时收费的现状容易引发收费争议和医患纠纷。笔者就在此背景下出现的智能吸氧计时系统的组成、工作原理、功能进行了详细的阐述。智能吸氧计时系统既能自动准确记录和保存患者的吸氧时间等信息,同时也为科学用氧的研... 目前国内医院吸氧计时收费的现状容易引发收费争议和医患纠纷。笔者就在此背景下出现的智能吸氧计时系统的组成、工作原理、功能进行了详细的阐述。智能吸氧计时系统既能自动准确记录和保存患者的吸氧时间等信息,同时也为科学用氧的研究提供了基础数据,是医疗吸氧的一次重大变革。 展开更多
关键词 智能吸氧计时系统 精密气流传感装置 自动
下载PDF
Studies on the in Vitro Dissolution of Insoluble Volatile Drug from Su-Anxin Nasal Inhalant and Its Correlation on the Nose Steady Self-Controllable Expiration and Inspiration at Night
3
作者 Xiaodong Li Guoxiang Xie +1 位作者 Suyun Li Chao Hou 《Pharmacology & Pharmacy》 2011年第2期67-72,共6页
In the paper, the in vitro dissolution of borneol in 12 hours from 6 batches of optimized inhalant samples were investigated. As a new dosage form, the in vitro release apparatus of nasal inhalant was invented and a p... In the paper, the in vitro dissolution of borneol in 12 hours from 6 batches of optimized inhalant samples were investigated. As a new dosage form, the in vitro release apparatus of nasal inhalant was invented and a pushing bump was used according to the simulation of the nose expiration and inspiration. Based on the data of r2 in the profile and similar factor f2 from 6 linear release tendencies, a good controlled release and a zero order tendency were observed. It can be suggested that there is a good correlation between the in vitro controlled release and the nose steady self-controllable expiration and inspiration, which will contribute to the trend of insoluble volatile drug controlled release and the effect of quick absorption in nasal pulmonary delivery to cure severe or acute cardiovascular or lung diseases at patients' sleeping, such as angina or breathing obstruction. Also, it was concluded that the prescription composed of insoluble volatile drugs can be prepared to be nasal inhalant from which drugs can be absorbed through nose steady self-controllable inspiration to the lung then into the blood and have a great effectiveness improvement of bioavailability at night timing drug delivery system. 展开更多
关键词 Su-Anxin NASAL inhalANTS INSOLUBLE VOLATILE Drugs timing DRUG Delivery System In Vitro Dissolution Controlled Release
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部